Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

775P - A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial

Date

21 Oct 2023

Session

Poster session 11

Topics

Tumour Site

Ovarian Cancer

Presenters

David SP Tan

Citation

Annals of Oncology (2023) 34 (suppl_2): S507-S542. 10.1016/S0923-7534(23)01937-3

Authors

D.S. Tan1, T.Z. Tan2, J. Ye3, N.Y.L. Ngoi4, A. Ogasawara5, D. Shintani6, A. Kurosaki6, K. Yamamoto7, Y. Jan8, S. Chen9, K. Fujiwara6, R. Huang10, K. Hasegawa11

Author affiliations

  • 1 Medical Oncology Department, NUHS - National University Health System, 119228 - Singapore/SG
  • 2 Genomics And Data Analytics, Cancer Science Institute (CSI) - National University of Singapore (NUS), 117599 - Singapore/SG
  • 3 Division Of Medical Oncology, National Cancer Centre Singapore, 168583 - Singapore/SG
  • 4 Department Of Haematology-oncology, National University Cancer Institute Singapore, Singapore/SG
  • 5 Department Of Gynecologic Oncology, Saitama Medical University International Medical Center, 350-1298 - Hidaka/JP
  • 6 Gynecologic Oncology, Saitama Medical University International Medical Center, 350-1298 - Saitama/JP
  • 7 Department Of Biostatistics, Yokohama City University Hospital, 236-004 - Yokohama/JP
  • 8 Cancer Genomics Department, ACT Genomics Headquarters, 114 - Taipei City/TW
  • 9 Headquarters, ACT Genomics, 114 - Taipei/TW
  • 10 No. 1 Ren Ai Road Section 1, R1418, NTU - National Taiwan University - College of Medicine, 10051 - Taipei City/TW
  • 11 Gynecologic Oncology Department, Saitama Medical University International Medical Center, 350-1298 - Saitama/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 775P

Background

The phase 3 iPocc trial reported improved progression-free survival (PFS) in OC patients receiving IP over intravenous (IV) carboplatin with IV dose-dense paclitaxel. We sought to identify biomarkers that can predict sensitivity to IP therapy.

Methods

117 pre-treatment frozen samples were subjected to mRNA profiling (Affymetrix HTA 2.0) and ACT Genomics ACTOnco®+ next generation sequencing. Cox regression analyses were performed to identify genes significantly correlated with PFS following IP treatment (p < 0.05). Homologous recombination repair deficiency (HRD) is defined by loss-of-heterozygosity (LOH) score ≥ 0.48.

Results

Patients receiving IP (n=61) or IV (n=56) had similar clinico-pathological distributions. We identified a 72-gene signature that was significantly correlated with PFS in IP but not in IV patients. Tumors harboring a signature with reduced VEGFA/VEGFR2 and PI3K signaling had low IP resistant score (IPRS) and were associated with improved outcomes for IP therapy. There was no difference in IPRS between BRCA1/2 wildtype and mutant tumors (p = 0.55). HRD tumors had a significantly higher IPRS than non-HRD tumors (p = 0.03). A high IPRS was significantly correlated with poorer PFS after IP therapy (median: ∼18 months vs not reached/NR, p < 0.0001), with no correlation seen after IV therapy (median: 25 vs 24 months, p = 0.9). Low IPRS IP patients had improved PFS compared with low IPRS IV patients (median: NR vs 25 months, p = 0.0261). Paradoxically, when IPRS is high, IP patients have worse PFS than IV patients (median: ∼18 vs 24 months, p = 0.004). Low IPRS was also able to predict improved outcomes in appendiceal cancer patients receiving hyperthermic IP therapy with the DNA cross-linking agent mitomycin-c (median PFS: 4.4 vs 1.5 years, p = 0.01).

Conclusions

The IPRS shows promise in identifying a subset of OC patients likely to benefit from IP platinum treatment. Validation in a larger cohort is warranted.

Clinical trial identification

NCT01506856.

Editorial acknowledgement

Legal entity responsible for the study

National University of Singapore.

Funding

The National Medical Research Council Singapore; Pangestu Family Foundation Gynaecologicla Cancer Research fund.

Disclosure

D.S. Tan: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Merck Serono, Roche, Eisai, GSK, Takeda; Financial Interests, Personal, Advisory Board: AstraZeneca, Bayer, MSD, Eisai, Roche, Genmab, GSK, Boehringer Ingelheim; Financial Interests, Personal, Stocks/Shares: Asian Microbiome Library (AMiLi); Financial Interests, Institutional, Research Grant: Roche, Bayer, Karyopharm Therapeutics, AstraZeneca; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Bergen Bio; Financial Interests, Institutional, Local PI: Zeria Pharmaceutical Co Ltd., Bayer, Byondis B.V.; Financial Interests, Leadership Role, Ex society president: Gynecologic Cancer Group Singapore; Financial Interests, Member of Board of Directors: Gynaecologic Cancer Intergroup (GCIG); Financial Interests, Leadership Role, Ex- Chair: Asia-Pacific Gynecologic Oncology Trials Group (APGOT); Financial Interests, Institutional, Product Samples, Research Study: MSD, Eisai, AstraZeneca. N.Y.L. Ngoi: Financial Interests, Personal, Advisory Board: AstraZeneca, Merck, Pfizer; Financial Interests, Personal, Other, honoraria: MSD. K. Yamamoto: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical, CMIC holdings, Johokiko, Triceps, Kanagawa Medical Practitioners Association; Financial Interests, Personal, Other, Statistical analysis: Otsuka Pharmaceutical; Financial Interests, Personal, Other, Statistical consultation: J-Pharma, Craif, Kanagawa Prefectural Hospital Organization; Financial Interests, Institutional, Other, unlimited grant: Taiho Pharmaceutical; Financial Interests, Institutional, Other, Unlimited grant: Boehringer Ingelheim, Ono Pharmaceutical, Takeda Pharmaceutical, Bayer Yakuhin, Daiichi Sankyo, Astellas, Kyowa Kirin, Data Vehicle Inc., EP Croit. Y. Jan, S. Chen: Financial Interests, Personal, Full or part-time Employment: ACT Genomics. K. Fujiwara: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, Takeda; Financial Interests, Personal, Advisory Board: MSD, Eisai, Genmab, Nano Carrier, Daiichi Sankyo, Seagen; Financial Interests, Personal, Other, Travel Expense: Clovis; Financial Interests, Institutional, Funding: Regenerone; Financial Interests, Institutional, Research Grant: MSD, Ono, Zeria, Genmab; Financial Interests, Personal and Institutional, Coordinating PI: AstraZeneca; Non-Financial Interests, Leadership Role: GOTIC. R. Huang: Financial Interests, Personal, Research Funding: Illumina. K. Hasegawa: Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, Takeda, Chugai, Genmab, Kaken, Eisai, Sanofi, GSK; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Funding, contracted research: MSD, Ono, Daiichi Sankyo, Eisai, Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.